InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
07 mars 2024 08h00 HE | Interpace Biosciences, Inc.
 ●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
08 nov. 2023 15h29 HE | Interpace Biosciences, Inc.
 ●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
09 août 2023 12h30 HE | Interpace Biosciences, Inc.
 ●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
10 juil. 2023 15h59 HE | Interpace Biosciences, Inc.
Q2 Revenue of $11 million; a 49.1% increase year-over-year and 12.2% better than Q1; highest quarter in history1st Half Revenue $20.9 million; 36.1% improvement over 1st Half 2022Q2 Test volume up...
InterpaceBiosciences_New Logo.png
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
05 juin 2023 16h05 HE | Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS)...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
12 mai 2023 16h05 HE | Interpace Biosciences, Inc.
 ●Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ●Q1 Test volume up nearly 20% year over year to record levels ●Q1 41.9 million covered lives added, resulting...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
27 mars 2023 16h05 HE | Interpace Biosciences, Inc.
 ●Q4 Revenue of $8.3 million  ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
14 nov. 2022 16h41 HE | Interpace Biosciences, Inc.
Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE)...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting
20 oct. 2022 16h28 HE | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
01 sept. 2022 17h18 HE | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...